OVERVIEW OF DIAGNOSIS AND TREATMENT OF FEMALE HYPOACTIVE SEXUAL DESIRE DISORDER
Main Article Content
Abstract
Background: Female sexual dysfunction has only been studied from a modern perspective
for more than six decades and is evolving rapidly [1]. “Female hypoactive sexual desire
disorder” was first reported in the DSM-III 41 years ago [2], however, so far the understanding
of physiology, pathogenesis, diagnosis, and treatment is still limited.
Aim: To develop an overview of the diagnosis, approach, and treatment of female hypoactive
sexual desire disorder.
Methods: Synthesis and analysis of studies on female hypoactive sexual desire disorder
and the latest guidelines on diagnosis and treatment of the International Society for the
Study of Women’s Sexual Health, the International Consultation on Sexual Medicine, The
International Society for Sexual Medicine.
Results: Complete an update on the diagnosis and treatment of female hypoactive sexual
desire disorder.
Conclusions: The Decreased Sexual Desire Screener is essential to screen for female
hypoactive sexual desire disorder. Asking about the disease, and exploiting psychological,
physiological, relationship, and social factors are extremely important for diagnosis and
treatment orientation. The treatment of female hypoactive sexual desire disorder may engage
both psychosocial and biological strategies. This review aims is to develop an overview of
the diagnosis, approach, and treatment of female hypoactive sexual desire disorder.
Article Details
Keywords
Female sexual dysfunction, female hypoactive sexual desire disorder.
References
and Dysfunction Study, Diagnosis and
Treatment, pp 3, 2005.
[2] American Psychiatric Association, DSM‐
III: Diagnostic and Statistical Manual of
Mental Disorders, 3rd edn. Washington, DC:
American Psychiatric Association, 1980.
[3] Irwin Goldstein, Textbook of Female Sexual
Function and Dysfunction: Diagnosis and
Treatment, John Wiley & Sons, Hoboken,
2018.
[4] Shifren JL, Monz BU, Russo PA et al.,
Sexual problems and distress in United
States women: prevalence and correlates.
Obstet Gynecol; 112(5):970–978, 2008.
[5] Dennerstein L, Koochaki P, Barton I et
al., Hypoactive sexual desire disorder in
menopausal women: A survey of Western
European women. J Sex Med; 3:212–222,
2006.
[6] Leiblum S, Symonds T, Moore J et al., A
methodology study to develop and validate
a screener for hypoactive sexual desire
disorder in postmenopausal women. J Sex
Med;3:455-464, 2006.
[7] Clayton AH, Goldfischer ER, Goldstein I
et al., Validation of the Decreased Sexual
Desire Screener (DSDS): a brief diagnostic
instrument for generalized acquired female
hypoactive sexual desire disorder (HSDD). J
Sex Med 2009;6:730-738, 2009.
[8] Clayton AH, Goldstein I, Kim NN et al.,
The International Society for the Study of
Women’s Sexual Health Process of Care for
Management of Hypoactive Sexual Desire
Disorder in Women. Mayo Clin Proc. 2018
Apr;93(4):467-487, 2018.
[9] Khera M, Testosterone therapy for female
sexual dysfunction. (2015). Sex Med Rev;
3:137.
[10] Stahl SM, Sommer B, Allers KA,
Multifunctional pharmacology of flibanserin:
possible mechanism of therapeutic action
in hypoactive sexual desire disorder. J Sex
Med;8(1):15-27, 2011.
[11] Katz M, DeRogatis LR, Ackerman R et al.,
BEGONIA Trial Investigators. Efficacy of
flibanserin in women with hypoactive sexual
desire disorder: results from the BEGONIA
trial. J Sex Med;10(7):1807-1815, 2013.
[12] Thorp J, Simon J, Dattani D et al., DAISY
Trial Investigators. Treatment of hypoactive
sexual desire disorder in premenopausal
women: efficacy of flibanserin in the DAISY
study. J Sex Med;9(3):793-804, 2012.
[13] Derogatis LR, Komer L, Katz M et al.,
VIOLET Trial Investigators. Treatment
of hypoactive sexual desire disorder
in premenopausal women: efficacy of
flibanserin in the VIOLET Study. J Sex
Med;9(4):1074-1085, 2012.
[14] ADDYI (flibanserin) [package insert].
Bridgewater, NJ: Sprout Pharmaceuticals,
2016.
[15] Kingsberg SA, Clayton AH, Pfaus JG, The
female sexual response: current models,
neurobiological underpinnings and agents
currently approved or under investigation
for the treatment of hypoactive sexual desire
disorder. CNS Drugs; 29(11):915-933, 2015.
[16] Goldstein I, Kim NN, Clayton AH et
al., Hypoactive Sexual Desire Disorder:
International Society for the Study of
Women’s Sexual Health (ISSWSH) Expert
Consensus Panel Review. Mayo Clin
Proc;92(1):114-128, 2017.
[17] Wierman ME, Arlt W, Basson R et al.,
Androgen therapyin women: a reappraisal:
an Endocrine Society clinical practice
guideline. J Clin Endocrinol Metab;
99:3489, 2014.
[18] Nastri CO, Lara LA, Ferriani RA et al.,
Hormone therapy for sexual function
in perimenopausal and postmenopausal
women. Cochrane Database Syst
Rev;(6):CD009672, 2013.
[19] Poels S, Bloemers J, van Rooij K et al.,
Toward personalized sexual medicine (part
2): testosterone combined with a PDE5
inhibitor increases sexual satisfaction in
women with HSDD and FSAD, and a low
sensitive system for sexual cues. J Sex
Med;10:810-823, 2013.
[20] Kingsberg SA, Clayton AH, Portman D
et al., Bremelanotide for the Treatment
of Hypoactive Sexual Desire Disorder:
Two Randomized Phase 3 Trials. Obstet
Gynecol;134(5):899-908, 2019.